Additive Effect of Topical Nepafenac on Mydriasis in Patients With Diabetes Mellitus.
Journal
Eye & contact lens
ISSN: 1542-233X
Titre abrégé: Eye Contact Lens
Pays: United States
ID NLM: 101160941
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
pubmed:
11
9
2019
medline:
19
8
2021
entrez:
11
9
2019
Statut:
ppublish
Résumé
To evaluate the additive effect of topical nepafenac on pupil diameter (PD) in patients with diabetes mellitus (DM) and cataract. This prospective comparative study included the patients having cataract surgery with and without DM. Two consecutive PD measurements were taken using an automatic quantitative pupillometry system (MonPack One, Metrovision). A baseline measurement was taken, then one drop of nepafenac % 0.1 (Nevanac; Alcon, Fort Worth, TX) was instilled only to the eye that will be operated on (study eye). Cyclopentolate 1.0% (Sikloplejin; Abdi İbrahim, İstanbul, Turkey) was instilled to both eyes (study eye/fellow eye) 5 minutes later. The second measurement was taken at 1 hour after this application. The DM group consisted of 43 patients, and the control group consisted of 39 participants. The baseline PDs of both eyes were similar in the DM group (P=0.070) and the control group (P=0.345). The change in pupil size from baseline to mydriasis was statistically significantly greater in the study eyes (2.69±0.53) than fellow eyes (2.54±0.61) in the DM group (P=0.009), but there was no statistically significant difference in the control group (2.94±0.63 vs. 2.86±0.58). When the groups were compared, the PD changes were similar in the study eyes between groups (P=0.065), while the PD changes in the fellow eyes were lower in the DM group (P=0.017). Nepafenac has been shown additive effect on pupil dilation in diabetic patients before cataract surgery.
Identifiants
pubmed: 31503086
doi: 10.1097/ICL.0000000000000657
pii: 00140068-202009000-00011
doi:
Substances chimiques
Benzeneacetamides
0
Phenylacetates
0
nepafenac
0J9L7J6V8C
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
310-313Références
Yakaryilmaz FD, Ozturk ZA. Treatment of type 2 diabetes mellitus in the elderly. World J Diabetes 2017;8:278–285.
Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol 2018;14:88–98.
Smith AG, Singleton JR. Diabetic neuropathy. Continuum (Minneap Minn) 2012;18:60–84.
Gupta P, Verma N, Bhattacharya S, et al. Association of diabetic autonomic neuropathy with red blood cell aldose reductase activity. Can J Diabetes 2014;38:22–25.
Lerner AG, Bernabé-Ortiz A, Ticse R, et al. Type 2 diabetes and cardiac autonomic neuropathy screening using dynamic pupillometry. Diabet Med 2015;32;1470–1478.
Luo P, Wang MH. Eicosanoids, β-cell function, and diabetes. Prostaglandins Other Lipid Mediat 2011;95:1–10.
Ferrari GL, Marques JL, Gandhi RA, et al. An approach to the assessment of diabetic neuropathy based on dynamic pupillometry. Conf Proc IEEE Eng Med Biol Soc 2007;2007:557–560.
Chawla A, Chawla R, Jaggi S. Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum? Indian J Endocrinol Metab 2016;20:546–551.
Ahuja M, Dhake AS, Sharma SK, et al. Topical ocular delivery of NSAIDs. AAPS J 2008;10:229–241.
Lane SS, Modi SS, Lehmann RP. Nepafenac suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. J Cataract Refract Surg 2007;33:53–58.
Lane SS. Nepafenac: A unique nonsteroidal prodrug. Int Ophthalmol Clin 2006;46:13–20.
Walters T, Raizman M, Ernest P, et al. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg 2007;33:1539–1545.
Shanmugam N, Gaw G, Natarajan IR. Molecular mechanisms of high glucose-induced cyclooxygenase-2 expression in monocytes. Diabetes 2004;53:795–802.
Cipollone F, Iezzi A, Fazia M, et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: Role of glycemic control. Circulation 2003;108:1070–1077.
Podos SM. Prostaglandins, nonsteroidal anti-inflammatory agents and eye disease. Trans Am Ophthalmol Soc 1976;74:637–660.
Rodríguez-García A, Hernández-Camarena JC, López-Jaime GR, et al. Effect of topical nonsteroidal anti-inflammatory drugs on pupillary size during uncomplicated cataract surgery. J Refract Surg 2017;33:236–242.
Singh RP, Lehmann R, Martel J, et al. Nepafenac 0.3% after cataract surgery in patients with diabetic retinopathy: Results of 2 randomized phase 3 studies. Ophthalmology 2017;124:776–785.
Jung JW, Chung BH, Kim EK, et al. The effects of two non-steroidal anti-inflammatory drugs, bromfenac 0.1% and ketorolac 0.45%, on cataract surgery. Yonsei Med J 2015;56:1671–1677.
Cervantes-Coste G, Sánchez-Castro YG, Orozco-Carroll M, et al. Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac. Clin Ophthalmol 2009;3:219–226.
Sarkar S, Mondal KK, Roy SS, et al. Comparison of preoperative nepafenac (0.1%) and flurbiprofen (0.03%) eye drops in maintaining mydriasis during small incision cataract surgery in patients with senile cataract: A randomized, double-blind study. Indian J Pharmacol 2015;47:491–495.
Papa V, Russo S, Russo P, et al. Topical naproxen sodium for inhibition of miosis during cataract surgery. Prospective, randomized clinical trials. Eye (Lond) 2002;16:292–296.
Keates RH, McGowan KA. The effect of topical indomethacin ophthalmic solution in maintaining mydriasis during cataract surgery. Ann Ophthalmol 1984;16:1116–1121.
Chastain JE, Sanders ME, Curtis MA, et al. Distribution of topical ocular nepafanac and its active metabolite amfenac to the posterior segment of the eye. Exp Eye Res 2016;145:58–67.
Rowen S. Preoperative and postoperative medications used for cataract surgery. Curr Opin Ophthalmol 1999;10:29–35.
Jain M, Devan S, Jaisankar D, et al. Pupillary abnormalities with varying severity of diabetic retinopathy. Sci Rep 2018;8:5636.
Cahill M, Eustace P, de Jesus V. Pupillary autonomic denervation with increasing duration of diabetes mellitus. Br J Ophthalmol 2001;85:1225–1230.
Yilmaz I, Faiz M, Saracoglu B, et al. Changes in pupil size following panretinal and focal/grid retinal photocoagulation: Automatic infrared pupillometry study. J Ocul Pharmacol Ther 2016;32:172–177.